- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06337552
Intervento alimentare ad alta fermentazione tra pazienti affetti da cancro del retto localmente avanzato (esperimento FEED)
Un intervento randomizzato con alimenti ad alta fermentazione tra pazienti affetti da cancro del retto localmente avanzato (esperimento FEED)
The purpose of the study is to evaluate the feasibility and acceptability of a dietary intervention (FEED-FF) that includes fermented foods (FF), among locally advanced rectal cancer patients and non-small cell lung cancer (NSCLC) patients, and to explore whether this diet can improve outcomes in rectal cancer patients receiving chemoradiation and NSCLC patients receiving immunotherapy.
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Florida
-
Tampa, Florida, Stati Uniti, 33612
- Moffitt Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria for GI Patients:
- 18 years of age or older
- Diagnosed with locally advanced rectal cancer (Stage II-III)
- Will undergo neoadjuvant chemoradiation at Moffitt Cancer Center
- Able to pick up FFs once/weekly at Moffitt
- Able to speak and read English
- Able to consume foods orally
- Able to provide informed consent
Inclusion Criteria for Thoracic Patients:
- 18 years of age or older
- Diagnosed with stage II-IV non-small cell lung cancer (NSCLC)
- Will undergo Immunotherapy with immune checkpoint inhibitors (+/- chemotherapy or other treatment) at Moffitt Cancer Center
- Able to pick up FFs once/weekly at Moffitt
- Able to speak and read English
- Able to consume foods orally
- Able to provide informed consent
Exclusion Criteria:
- Antibiotic use within 1 month prior to baseline
- If currently using probiotics, unwillingness to cease probiotic use
- Previous receipt of surgery, immunotherapy, chemotherapy, or radiation for a colon or rectal tumor
- Per clinician's discretion, clinician confirmed inflammatory bowel conditions (e.g., ulcerative colitis, Crohn's disease)
- Infectious disease diagnosed <1 month prior to baseline
- Already consuming ≥2 servings of fermented foods/day
- Previously diagnosed with a mast cell disorder or histamine allergy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: FEED-FF
Participants will be asked to pick up the fermented foods at the Research Kitchen at Moffitt. Participants will be asked to eat 3-6 servings of FFs per day, from 1 week prior to treatment start through 12 weeks after treatment start/until the restaging scope is completed. At baseline, the end of week 6.5 and again at week 12.5, participants will be asked to provide biospecimens including a stool sample collected at home and a blood specimen collected in clinic. Participants will be asked to complete a food frequency questionnaire, a quality-of-life survey, two symptom related surveys, and a stool collection questionnaire at these same timepoints. After the dietary intervention, participants will be asked to complete an exit survey to provide feedback on the study and intervention. |
3-6 servings of any combination of the following fermented foods/day (from 1 week prior to treatment to approximately 12 weeks after the start of treatment): Yogurt, cottage cheese, kefir, kombucha, sauerkraut, and kimchi. |
|
Comparatore attivo: Standard of Care (SUC)
Participants will receive general healthy eating handouts similar to current usual care documents provided in clinic. These handouts will detail typical healthy foods and the suggested level of intake, or servings per day. At baseline, the end of week 6.5 and again at week 12.5, participants will be asked to provide biospecimens including a stool sample collected at home and a blood specimen collected in clinic. Participants will be asked to complete a food frequency questionnaire, a quality-of-life survey, two symptom related surveys, and a stool collection questionnaire at these same timepoints. |
Standard of Care (SUC) is the treatment that is accepted by medical experts as a proper treatment for a certain type of disease and that is widely used by health care professionals. Standard of Care will comprise general healthy eating handouts that describe typical healthy foods and the suggested level of servings per day. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Effects of the FEED-FF diet on clinical response to chemoradiation (Rectal Cancer Patients)
Lasso di tempo: At Baseline and Up to 12.5 Weeks
|
Clinical response measured in clinic by MRI/Endoscopy/Digital rectal exam, comparing the FEED-FF arm to SUC arm. Indicators of clinical response are Complete Response, Near Complete Response, Incomplete Response, or Progressive Disease. |
At Baseline and Up to 12.5 Weeks
|
|
Effects of the FEED-FF diet on clinical response to immunotherapy (Lung Cancer Patients)
Lasso di tempo: At Baseline and Up to 12.5 Weeks
|
Clinical benefit to immune checkpoint inhibitor therapy will be measured in clinic by MRI/Endoscopy, comparing the FEED-FF arm to SUC arm. Defined as the best response of complete tumor resolution (CR), Partial Response (PR), and stable tumor size (SD) within 12 months. Progressive Disease (PD) within 12 months indicates no clinical benefit. |
At Baseline and Up to 12.5 Weeks
|
|
Effects of FEED-FF diet on the gut microbiome
Lasso di tempo: At Baseline, Week 6.5 and Up to 12.5 Weeks
|
Measured by fecal biospecimen sample collection; FEED-FF arm hypothesized to demonstrate increases in short chain fatty acid (SCFA) producing bacteria and higher alpha diversity compared to SUC arm. |
At Baseline, Week 6.5 and Up to 12.5 Weeks
|
|
Effects of FEED-FF diet on local immune-related biomarkers
Lasso di tempo: At Baseline and Up to 12.5 Weeks
|
Measured by FFPE tissue slides; FEED-FF arm hypothesized to demonstrate enhanced immune response such as higher T-cell expression compared to SUC arm. |
At Baseline and Up to 12.5 Weeks
|
|
Effects of FEED-FF diet on quality of life
Lasso di tempo: At Baseline, Week 6.5 and Up to 12.5 Weeks
|
Measured by using the European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Survey; FEED-FF arm hypothesized to demonstrate more favorable QoL compared to SUC arm. |
At Baseline, Week 6.5 and Up to 12.5 Weeks
|
|
Efficacy of the FEED-FF intervention
Lasso di tempo: At Baseline, Week 6.5 and Up to 12.5 Weeks
|
Measured by an accrual rate of 50% of eligible patients, fermented foods (FF) intake of at least 3 servings on at least 80% of days, and at least 80% of intervention group reporting high/very high satisfaction with intervention. Weekly goal adherence via randomly administered food logs, tracking responses to and general completion of an exit survey will be utilized. |
At Baseline, Week 6.5 and Up to 12.5 Weeks
|
|
Feasibility of the FEED-FF intervention
Lasso di tempo: At Baseline, Week 6.5 and Up to 12.5 Weeks
|
Measured by an accrual rate of 50% of eligible patients, fermented foods (FF) intake of at least 3 servings on at least 80% of days, and at least 80% of intervention group reporting high/very high satisfaction with intervention. Weekly goal adherence via randomly administered food logs, tracking responses to and general completion of an exit survey will be utilized. |
At Baseline, Week 6.5 and Up to 12.5 Weeks
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Doratha (Armen) Byrd, PhD, MPH, Moffitt Cancer Center
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie intestinali
- Malattie delle vie respiratorie
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Neoplasie colorettali
- Neoplasie intestinali
- Malattie del retto
- Malattie polmonari
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Neoplasie polmonari
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Neoplasie Rettali
- Carcinoma, polmone non a piccole cellule
- Amministrazione dei servizi sanitari
- Qualità, accesso e valutazione dell'assistenza sanitaria
- Qualità dell'assistenza sanitaria
- Indicatori di qualità, assistenza sanitaria
- Standard di cura
Altri numeri di identificazione dello studio
- MCC-22709
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .